We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FOLD Stock Rises on Settling Galafold Patent Dispute With Teva
Read MoreHide Full Article
Amicus Therapeutics (FOLD - Free Report) announced that it has signed a licensing agreement with Teva Pharmaceuticals (TEVA - Free Report) , which resolves the patent lawsuit filed earlier by FOLD. The litigation arose after Teva submitted an abbreviated new drug application seeking approval to sell a generic version of Amicus' Galafold (migalastat) 123 mg capsules before the related patents expired. The stock jumped 14% on Thursday as investors cheered the dispute settlement with TEVA.
Galafold, Amicus’ lead marketed drug, is the first and only approved oral medicine for patients living with Fabry disease, having amenable genetic variants.
Under the terms of the agreement, Amicus will grant Teva a license to sell its generic version of Galafold in the United States starting Jan. 30, 2037, pending FDA approval and subject to the fulfillment of certain customary conditions. The agreement ends all ongoing litigation between Amicus and Teva concerning Galafold patents in the U.S. District Court for Delaware. However, the litigation will continue against Aurobindo Pharma as the remaining active party, and the litigation stay remains in place for Lupin.
The companies will submit the confidential license agreement for review by the U.S. Federal Trade Commission and the Department of Justice, as required by law. Amicus’ shares jumped 14% on Thursday as investors cheered the dispute settlement with TEVA.
Year to date, shares of FOLD have plunged 15.6% compared with the industry’s 1.3% decline.
Image Source: Zacks Investment Research
Galafold – A Key Growth Driver for Amicus
Galafold has shown solid uptake since launch driven by continued demand. The sales of the drug have been rising consistently year over year. In the first six months of 2024, the drug generated sales worth $210.2 million, which increased 17% year over year at a constant currency basis. Galafold is currently approved in several countries, including the United States, EU, United Kingdom and Japan.
Owing to continued global uptake and sustained patient demand, FOLD increased Galafold's revenue guidance for 2024 in the second-quarter earnings release. The company now anticipates its total Galafold revenues to grow in the range of 14-18% compared with the previous guidance of 13-17%. The drug also has a strong intellectual property portfolio in the United States, providing patent protection through 2038. Label expansion, along with approvals in additional geographies, is likely to drive sales of the drug further in the days ahead.
Pompe Disease Drug – An Incremental Source of Revenues
Amicus also has a second FDA-approved drug in its commercial portfolio. In September 2023, the FDA approved Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) 65mg capsules, a two-component therapy for treating late-onset Pompe disease (LOPD) in adults who weigh more than 40 kg and are not improving on their current enzyme replacement therapy.
The approval for Pombiliti + Opfolda in the United States is a huge boost and provides a significant commercial opportunity for Amicus in the long run.
Pombiliti + Opfolda is also approved in the EU, including the United Kingdom, for treating LOPD in adults. The drugs are witnessing a strong launch so far, which continues to build momentum with an increasing rate of commercial patient starts.
Although the combo drug is yet to gain traction in the market, its approval and consequent launch in multiple geographies have relieved the significant burden on Galafold to generate revenues for Amicus.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share (EPS) have moved up from $4.69 to $4.81. EPS estimates for 2025 have improved from $5.37 to $5.86, during the same period. Year to date, shares of ANIP have gained 9%.
ANI Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 31.32%.
In the past 60 days, estimates for Alnylam’s 2024 loss per share have narrowed from $1.20 to 63 cents. Loss per shares estimates for 2025 have narrowed from 34 cents to 26 cents, during the same period. Year to date, shares of ALNY have risen 55%.
Alnylam’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 108.53%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
FOLD Stock Rises on Settling Galafold Patent Dispute With Teva
Amicus Therapeutics (FOLD - Free Report) announced that it has signed a licensing agreement with Teva Pharmaceuticals (TEVA - Free Report) , which resolves the patent lawsuit filed earlier by FOLD. The litigation arose after Teva submitted an abbreviated new drug application seeking approval to sell a generic version of Amicus' Galafold (migalastat) 123 mg capsules before the related patents expired. The stock jumped 14% on Thursday as investors cheered the dispute settlement with TEVA.
Galafold, Amicus’ lead marketed drug, is the first and only approved oral medicine for patients living with Fabry disease, having amenable genetic variants.
Under the terms of the agreement, Amicus will grant Teva a license to sell its generic version of Galafold in the United States starting Jan. 30, 2037, pending FDA approval and subject to the fulfillment of certain customary conditions. The agreement ends all ongoing litigation between Amicus and Teva concerning Galafold patents in the U.S. District Court for Delaware. However, the litigation will continue against Aurobindo Pharma as the remaining active party, and the litigation stay remains in place for Lupin.
The companies will submit the confidential license agreement for review by the U.S. Federal Trade Commission and the Department of Justice, as required by law. Amicus’ shares jumped 14% on Thursday as investors cheered the dispute settlement with TEVA.
Year to date, shares of FOLD have plunged 15.6% compared with the industry’s 1.3% decline.
Image Source: Zacks Investment Research
Galafold – A Key Growth Driver for Amicus
Galafold has shown solid uptake since launch driven by continued demand. The sales of the drug have been rising consistently year over year. In the first six months of 2024, the drug generated sales worth $210.2 million, which increased 17% year over year at a constant currency basis. Galafold is currently approved in several countries, including the United States, EU, United Kingdom and Japan.
Owing to continued global uptake and sustained patient demand, FOLD increased Galafold's revenue guidance for 2024 in the second-quarter earnings release. The company now anticipates its total Galafold revenues to grow in the range of 14-18% compared with the previous guidance of 13-17%. The drug also has a strong intellectual property portfolio in the United States, providing patent protection through 2038. Label expansion, along with approvals in additional geographies, is likely to drive sales of the drug further in the days ahead.
Pompe Disease Drug – An Incremental Source of Revenues
Amicus also has a second FDA-approved drug in its commercial portfolio. In September 2023, the FDA approved Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) 65mg capsules, a two-component therapy for treating late-onset Pompe disease (LOPD) in adults who weigh more than 40 kg and are not improving on their current enzyme replacement therapy.
The approval for Pombiliti + Opfolda in the United States is a huge boost and provides a significant commercial opportunity for Amicus in the long run.
Pombiliti + Opfolda is also approved in the EU, including the United Kingdom, for treating LOPD in adults. The drugs are witnessing a strong launch so far, which continues to build momentum with an increasing rate of commercial patient starts.
Although the combo drug is yet to gain traction in the market, its approval and consequent launch in multiple geographies have relieved the significant burden on Galafold to generate revenues for Amicus.
Amicus Therapeutics, Inc. Price and Consensus
Amicus Therapeutics, Inc. price-consensus-chart | Amicus Therapeutics, Inc. Quote
FOLD’s Zacks Rank and Other Stocks to Consider
Amicus currently sports a Zacks Rank #1 (Strong Buy).
Some other top-ranked stocks in the biotech sector are ANI Pharmaceuticals (ANIP - Free Report) and Alnylam Pharmaceuticals (ALNY - Free Report) . While ANIP sports a Zacks Rank #1, ALNY carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share (EPS) have moved up from $4.69 to $4.81. EPS estimates for 2025 have improved from $5.37 to $5.86, during the same period. Year to date, shares of ANIP have gained 9%.
ANI Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 31.32%.
In the past 60 days, estimates for Alnylam’s 2024 loss per share have narrowed from $1.20 to 63 cents. Loss per shares estimates for 2025 have narrowed from 34 cents to 26 cents, during the same period. Year to date, shares of ALNY have risen 55%.
Alnylam’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 108.53%.